Shares of Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR) crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of C$13.76 and traded as high as C$15.00. Cipher Pharmaceuticals shares last traded at C$14.17, with a volume of 89,992 shares changing hands.
Cipher Pharmaceuticals Price Performance
The stock has a market cap of C$360.13 million, a PE ratio of 12.65 and a beta of 1.29. The stock’s fifty day moving average is C$13.76 and its 200-day moving average is C$15.73. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.59 and a quick ratio of 2.67.
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last issued its earnings results on Thursday, November 12th. The company reported C$0.60 EPS for the quarter. The company had revenue of C$18.08 million for the quarter. Cipher Pharmaceuticals had a net margin of 58.81% and a return on equity of 22.74%. As a group, equities analysts anticipate that Cipher Pharmaceuticals Inc. will post 1.29 EPS for the current year.
Insider Activity
In other news, Director Craig Mull purchased 20,000 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was acquired at an average price of C$14.16 per share, for a total transaction of C$283,200.00. Following the acquisition, the director directly owned 1,009,953 shares of the company’s stock, valued at approximately C$14,300,934.48. This represents a 2.02% increase in their ownership of the stock. 42.00% of the stock is owned by corporate insiders.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.
Further Reading
- Five stocks we like better than Cipher Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
